Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,343 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Serum Clear all
Not yet recruiting Phase 2 Interventional

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

NCT07588698
View directory record Official record
Conditions
Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone, Positron Emission Tomography (PET), Blood specimen collection, Questionnaires, Computerized tomography (CT)
Drug · Procedure · Behavioral
Lead sponsor
Carrie Ho, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

NCT00160693
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
29
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Estradiol Levels in Patients Treated With Estring

NCT01923298
View directory record Official record
Conditions
Estrogen Levels Among Breast Cancer Patients
Interventions
Estradiol
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00118287
View directory record Official record
Conditions
de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
Interventions
azacitidine, etanercept
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 3, 2026, 5:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cholate Clearance in Fontan and Heart Failure

NCT07009132
View directory record Official record
Conditions
Fontan, Right Heart Failure
Interventions
Dual cholate clearance assay, MRI
Device · Radiation
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Not applicable Interventional

The Effects of Fiber Fortified Foods to the Diets of Chronic Kidney Disease Patients

NCT01842087
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Control Food, Fiber Fortified Food
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

NCT01564784
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
96
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

NCT01251978
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
Ranibizumab 2 mg, 0.5 mg Ranibizumab
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Bone Marrow Failure Syndromes

NCT00176878
View directory record Official record
Conditions
Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Interventions
Stem cell transplant, Fludarabine monophosphate, Total lymphoid irradiation, Busulfan, anti-thymocyte globulin
Procedure · Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

NCT00057343
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Zevalin (ibritumomab tiuxetan), Rituxan (rituximab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
67
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

NCT03619876
View directory record Official record
Conditions
Rheumatoid Arthritis, Myocardial Inflammation
Interventions
Abatacept, Adalimumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 3, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

NCT05786040
View directory record Official record
Conditions
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Rituximab, Tafasitamab
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

NCT01025089
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Interventions
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
8
States / cities
Duarte, California • Basking Ridge, New Jersey • Commack, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

NCT01256385
View directory record Official record
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 3, 2026, 5:35 PM EDT
Not listed No phase listed Observational

Biomarkers of Independent Walking Post-Stroke

NCT05004389
View directory record Official record
Conditions
Stroke, Acute, Gait, Hemiplegic
Interventions
MRI, blood draw, Clinical assessments
Diagnostic Test · Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 2 Interventional

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

NCT00137774
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Bevacizumab, Temozolomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

NCT00077233
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
77
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

NCT03364738
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
rhPTH(1-84)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Lexington, Kentucky • Metairie, Louisiana • Reno, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 3, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 3, 2026, 5:35 PM EDT
Not listed Not applicable Interventional

Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test

NCT04670926
View directory record Official record
Conditions
Kidney Transplant Rejection, Immunosuppression
Interventions
TruGraf, Standard of Care
Diagnostic Test · Other
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 3, 2026, 5:35 PM EDT
Withdrawn Phase 2 Interventional

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02538926
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory B Lymphoblastic Lymphoma, Refractory T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Asparaginase, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00280150
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

NCT01853748
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Paclitaxel, Trastuzumab emtansine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
85
States / cities
Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 3, 2026, 5:35 PM EDT